DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR EPINASTINE HYDROCHLORIDE

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

All Clinical Trials for Epinastine Hydrochloride

Subscribe to access the full database, or Start Trial
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00407927	A Study of Epinastine Nasal Spray in Subjects With Seasonal Allergic Rhinitis	Completed	Merck Sharp & Dohme Corp.	Phase 2	2006-12-01	The purpose of this trial is to determine the safety, efficacy and tolerability of two doses of the study drug compared to placebo for the treatment of subjects with seasonal allergic rhinitis.
NCT00489398	Comparison of CL Wear Between Two Allergy Drops	Withdrawn	Merck Sharp & Dohme Corp.	Phase 4	2007-07-01	Comparison of two allergy drops for enhancing comfort and performance of contact lens wear
NCT00489398	Comparison of CL Wear Between Two Allergy Drops	Withdrawn	Hom, Milton M., OD, FAAO	Phase 4	2007-07-01	Comparison of two allergy drops for enhancing comfort and performance of contact lens wear
NCT00564421	Safety and Efficacy Study of Epinastine Nasal Spray in Subjects With Seasonal Allergic Rhinitis (P08648)	Completed	Merck Sharp & Dohme Corp.	Phase 3	2007-12-01	The purpose of this study is to determine the safety and efficacy of epinastine nasal spray compared to placebo for the treatment of subjects with seasonal allergic rhinitis
NCT01382654	Two Formulations and Concentrations of Epinastine Nasal Spray Versus Azelastine Nasal Solution for Allergic Rhinitis	Completed	Merck Sharp & Dohme Corp.	Phase 2	2006-09-01	The objectives of this study were to: - Examine the tolerability of two formulations and two dose concentrations of epinastine. - Select formulation(s) of epinastine for future studies by evaluating the individual sensory attribute scores of the Nasal Spray Evaluation Questionnaire (NSEQ) collected after each study drug administration and the subject preference ranking assessed at the completion of the study. - Compare the preference of two formulations and two dose concentrations of epinastine compared to azelastine following a single dose of each in a randomized, double-blind, two-cohort, three-period crossover design.
NCT01569191	Non-Pharmaceutical Treatment of Seasonal Allergic Conjunctivitis	Completed	University of Worcester	Phase 4	2012-03-01	Seasonal allergic conjunctivitis (SAC) is an irritating eye condition that affects many people, caused by hypersensitivity to normally harmless substances such as pollen, and often accompanies seasonal hay fever. Treatments that can be used before initiating medical therapy include artificial tear supplements (ATS) and cold compresses (CC). However, there is no evidence in the scientific literature that demonstrates their efficacy compared to no treatment or their combined effect with anti-allergic medication. Therefore the investigators aim to examine the efficacy of ATS and CC alone, in comparison to anti-allergic medication, and CC in combination with anti-allergic medication. In addition, the investigators also aim to determine the time course of ocular allergic reactions. At the end of the study the investigators will be able to see whether or not ATS and CC are effective in treating SAC.
NCT01569191	Non-Pharmaceutical Treatment of Seasonal Allergic Conjunctivitis	Completed	Aston University	Phase 4	2012-03-01	Seasonal allergic conjunctivitis (SAC) is an irritating eye condition that affects many people, caused by hypersensitivity to normally harmless substances such as pollen, and often accompanies seasonal hay fever. Treatments that can be used before initiating medical therapy include artificial tear supplements (ATS) and cold compresses (CC). However, there is no evidence in the scientific literature that demonstrates their efficacy compared to no treatment or their combined effect with anti-allergic medication. Therefore the investigators aim to examine the efficacy of ATS and CC alone, in comparison to anti-allergic medication, and CC in combination with anti-allergic medication. In addition, the investigators also aim to determine the time course of ocular allergic reactions. At the end of the study the investigators will be able to see whether or not ATS and CC are effective in treating SAC.
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary